Target intelligence / Profile preview

Bladder urothelial permeability barrier restoration

Molecular classification
Other (process, not a molecule), may involve proteins from "Tight junction protein", "Uroplakin family"
01

Overview

The bladder urothelial permeability barrier restoration refers to the process by which the urinary bladder’s surface epithelium (urothelium) repairs itself after injury to restore its function as a highly effective barrier between urine and underlying tissues. The urothelium, especially its umbrella cell layer, normally exhibits exceptionally low permeability, due to the presence of specialized proteins such as uroplakins and tight junction components (e.g., ZO-1, claudins, occludin). Injury caused by chemical agents (e.g., protamine sulfate), infection, or disease can result in the sloughing of umbrella cells, increased permeability, and subsequent leakage of urine components into the bladder wall, leading to symptoms such as pain and inflammation. Restoration of the barrier involves proliferation and differentiation of intermediate urothelial cells into mature umbrella cells, re-formation of tight junctions, and re-expression of barrier proteins, typically within 2–5 days following the insult. Restoration is also the goal of certain therapies for bladder conditions, such as GAG replenishment treatment in interstitial cystitis and related disorders.

Other names
Bladder permeability barrier repairUrothelial barrier restorationUrothelial repair
02

Mechanism of action

GAG replenishment: restores mucosal GAG layer, reinforcing the permeability barrier Cellular repair: proliferation and differentiation of urothelial progenitor/intermediate cells into barrier-forming umbrella cells

03

Biological functions

Epithelial barrier restorationUrothelial regenerationTissue repairHomeostatic response following injury
04

Disease associations

Interstitial cystitis/bladder pain syndromeCystitis (infection/inflammation)Bladder injury (chemical, infectious, or mechanical insults)
05

Safety considerations

Delayed or inadequate barrier restoration may contribute to chronic pain, infection, or inflammation (e.g., interstitial cystitis/BPS)Off-target injury by therapies meant to augment repair
06

Interacting drugs

GAG (glycosaminoglycan) replenishment therapies (e.g., pentosan polysulfate, hyaluronic acid, chondroitin sulfate)

1 more in the full profile.

07

Biomarkers

Tight junction proteins (ZO-1, occludin, claudin-4/8/12)Uroplakin expression (particularly UPIII)Cytokeratin 20 (CK20, differentiation marker for umbrella cells)

Beyond the preview

Go deeper on Bladder urothelial permeability barrier restoration.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bladder urothelial permeability barrier restoration.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call